Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

Trial Details

NCT ID
NCT05192122
Phase
PHASE1
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Discontinue maintenance therapy SOC
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • ECOG Performance Status equal to or less than 2 within 30 days prior to registration
  • Revised International Staging System (R-ISS) I,2 or 3
  • Patients with multiple myeloma as defined by IMWG
  • Received at least 2 years of post ASCT maintenance (patients may have received any number of prior lines of therapy).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →